CN113773385B - 缓激肽b1受体配体的抗体 - Google Patents

缓激肽b1受体配体的抗体

Info

Publication number
CN113773385B
CN113773385B CN202111098640.7A CN202111098640A CN113773385B CN 113773385 B CN113773385 B CN 113773385B CN 202111098640 A CN202111098640 A CN 202111098640A CN 113773385 B CN113773385 B CN 113773385B
Authority
CN
China
Prior art keywords
ser
gly
tyr
thr
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111098640.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113773385A (zh
Inventor
H·李
D·科米诺斯
J·张
A·普里斯克
M·达文森
N·鲍林
G·萨布拉马尼安
X·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113773385(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN113773385A publication Critical patent/CN113773385A/zh
Application granted granted Critical
Publication of CN113773385B publication Critical patent/CN113773385B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202111098640.7A 2012-03-28 2013-03-15 缓激肽b1受体配体的抗体 Active CN113773385B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
US61/616845 2012-03-28
FR1350953 2013-02-04
FR1350953 2013-02-04
CN201380027405.8A CN104334578B (zh) 2012-03-28 2013-03-15 缓激肽b1受体配体的抗体
PCT/US2013/031836 WO2013148296A1 (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380027405.8A Division CN104334578B (zh) 2012-03-28 2013-03-15 缓激肽b1受体配体的抗体

Publications (2)

Publication Number Publication Date
CN113773385A CN113773385A (zh) 2021-12-10
CN113773385B true CN113773385B (zh) 2025-09-12

Family

ID=49261064

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380027405.8A Active CN104334578B (zh) 2012-03-28 2013-03-15 缓激肽b1受体配体的抗体
CN202510415465.1A Pending CN120441698A (zh) 2012-03-28 2013-03-15 缓激肽b1受体配体的抗体
CN202111098640.7A Active CN113773385B (zh) 2012-03-28 2013-03-15 缓激肽b1受体配体的抗体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201380027405.8A Active CN104334578B (zh) 2012-03-28 2013-03-15 缓激肽b1受体配体的抗体
CN202510415465.1A Pending CN120441698A (zh) 2012-03-28 2013-03-15 缓激肽b1受体配体的抗体

Country Status (38)

Country Link
US (5) US9376494B2 (enExample)
EP (2) EP3246339B1 (enExample)
JP (5) JP6779012B2 (enExample)
KR (4) KR102035882B1 (enExample)
CN (3) CN104334578B (enExample)
AR (1) AR090352A1 (enExample)
AU (2) AU2013240242B2 (enExample)
BR (1) BR112014024282A2 (enExample)
CA (1) CA2868353C (enExample)
CL (2) CL2014002590A1 (enExample)
CO (1) CO7111293A2 (enExample)
CR (1) CR20140440A (enExample)
CY (1) CY1121466T1 (enExample)
DK (2) DK3246339T3 (enExample)
DO (1) DOP2014000199A (enExample)
EA (1) EA201491784A1 (enExample)
ES (1) ES2673869T3 (enExample)
GT (1) GT201400192A (enExample)
HR (1) HRP20180928T1 (enExample)
HU (1) HUE037720T2 (enExample)
IL (1) IL234830B (enExample)
LT (1) LT2831113T (enExample)
MA (1) MA37407B1 (enExample)
MX (2) MX361874B (enExample)
MY (2) MY166157A (enExample)
NZ (1) NZ631543A (enExample)
PE (1) PE20142170A1 (enExample)
PH (1) PH12014501970A1 (enExample)
PL (1) PL2831113T3 (enExample)
PT (1) PT2831113T (enExample)
RS (1) RS57413B1 (enExample)
SG (2) SG10201702396QA (enExample)
SI (1) SI2831113T1 (enExample)
TR (1) TR201808486T4 (enExample)
TW (1) TWI605060B (enExample)
UA (1) UA117097C2 (enExample)
UY (1) UY34682A (enExample)
WO (1) WO2013148296A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2831113T (lt) * 2012-03-28 2018-06-25 Sanofi Antikūnai prieš bradikinino b1 receptoriaus ligandus
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
EP3390439B1 (en) 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
CN110881274B (zh) * 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
CN110913895B (zh) * 2017-05-08 2024-04-02 阿迪马布有限责任公司 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法
WO2019148186A1 (en) * 2018-01-29 2019-08-01 Silarus Therapeutics, Inc. Antibodies binding erfe and methods of use
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
CN119306824B (zh) * 2024-10-08 2025-09-26 江苏埃尔迪生物科技有限公司 一种全价展示scFv的通用型M13噬菌体探针及其构建方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334578A (zh) * 2012-03-28 2015-02-04 赛诺菲 缓激肽b1受体配体的抗体

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
CN101193654A (zh) * 2005-06-14 2008-06-04 赛托斯生物技术公司 抗原偶联物及其用途
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
CA2669921A1 (en) * 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
EP2157937B1 (en) 2007-06-04 2017-03-22 Sequent Medical, Inc. Devices for treatment of vascular defects
SG182192A1 (en) * 2007-06-12 2012-07-30 Ac Immune Sa Humanized antibodies to amyloid beta
SI2195023T1 (en) 2007-08-29 2018-07-31 Sanofi Humanized anti-CXCR5 antibodies, their derivatives and their uses
BRPI0820270A2 (pt) * 2007-11-07 2015-06-16 Celldex Therapeutics Inc Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334578A (zh) * 2012-03-28 2015-02-04 赛诺菲 缓激肽b1受体配体的抗体

Also Published As

Publication number Publication date
CL2014002590A1 (es) 2015-01-16
RS57413B1 (sr) 2018-09-28
DK2831113T3 (en) 2018-06-25
PT2831113T (pt) 2018-06-20
EP2831113B1 (en) 2018-03-14
MA37407A1 (fr) 2016-05-31
SG11201405162YA (en) 2014-09-26
GT201400192A (es) 2015-07-29
KR102166083B1 (ko) 2020-10-16
HRP20180928T1 (hr) 2018-07-27
NZ631543A (en) 2017-03-31
US20150050270A1 (en) 2015-02-19
EP2831113A1 (en) 2015-02-04
US20160368976A1 (en) 2016-12-22
CA2868353A1 (en) 2013-10-03
MX361874B (es) 2018-12-18
AR090352A1 (es) 2014-11-05
CO7111293A2 (es) 2014-11-10
US10465002B2 (en) 2019-11-05
CN104334578A (zh) 2015-02-04
JP6779012B2 (ja) 2020-11-04
IL234830B (en) 2018-11-29
KR102367723B1 (ko) 2022-02-28
AU2013240242B2 (en) 2018-02-08
KR102035882B1 (ko) 2019-10-24
MY166157A (en) 2018-06-06
CN104334578B (zh) 2021-10-08
JP2024038036A (ja) 2024-03-19
JP6912441B2 (ja) 2021-08-04
MA37407B1 (fr) 2018-03-30
MY184037A (en) 2021-03-17
JP2015513903A (ja) 2015-05-18
MX2014011688A (es) 2015-01-22
PL2831113T3 (pl) 2018-08-31
UA117097C2 (uk) 2018-06-25
CA2868353C (en) 2023-10-31
ES2673869T3 (es) 2018-06-26
BR112014024282A2 (pt) 2017-08-08
MX2018015914A (es) 2021-12-08
JP2019050822A (ja) 2019-04-04
US9376494B2 (en) 2016-06-28
TR201808486T4 (tr) 2018-07-23
KR20220031728A (ko) 2022-03-11
DOP2014000199A (es) 2014-10-31
CL2017003039A1 (es) 2018-03-16
KR20150002679A (ko) 2015-01-07
AU2018203081A1 (en) 2018-05-24
TWI605060B (zh) 2017-11-11
HUE037720T2 (hu) 2018-09-28
DK3246339T3 (da) 2020-01-27
PE20142170A1 (es) 2015-01-07
HK1206754A1 (en) 2016-01-15
WO2013148296A1 (en) 2013-10-03
LT2831113T (lt) 2018-06-25
KR20200121370A (ko) 2020-10-23
US20180222967A1 (en) 2018-08-09
EA201491784A1 (ru) 2015-02-27
CN120441698A (zh) 2025-08-08
JP2021166538A (ja) 2021-10-21
SI2831113T1 (en) 2018-08-31
CR20140440A (es) 2014-11-17
US9879079B2 (en) 2018-01-30
SG10201702396QA (en) 2017-04-27
CN113773385A (zh) 2021-12-10
AU2013240242A1 (en) 2014-10-02
EP3246339A1 (en) 2017-11-22
JP2025134874A (ja) 2025-09-17
US20200115441A1 (en) 2020-04-16
PH12014501970A1 (en) 2014-11-17
UY34682A (es) 2013-10-31
KR20190121861A (ko) 2019-10-28
US20230399388A1 (en) 2023-12-14
EP3246339B1 (en) 2019-10-09
TW201343671A (zh) 2013-11-01
JP7411609B2 (ja) 2024-01-11
CY1121466T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
CN113773385B (zh) 缓激肽b1受体配体的抗体
KR20160035077A (ko) 플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도
AU2014306649A1 (en) Antibodies to Plasminogen Activator inhibitor-1 (PAI-1) and uses thereof
HK40044528A (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
HK1206754B (en) Antibodies to bradykinin b1 receptor ligands
OA17139A (en) Antibodies to bradykinin B1 receptor ligands

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant